Latest Daily News

More Stories

July 23, 2018

In the following interview, internationally renowned cancer researcher and medical oncologist Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, of Carolinas HealthCare System’s Levine Cancer Institute, details his views on the field of immunotherapy in bladder cancer.

Read more

June 14, 2018

In a small population of patients with advanced castration-resistant prostate cancer (CRPC), the anti–PD-1 inhibitor pembrolizumab had some anticancer activity, according to the results of KEYNOTE-199 (Abstract 5007) presented on June 4.

Read more

June 14, 2018

Black men are more likely than white men to die as a result of prostate cancer in the United States.

Read more

June 14, 2018

PARP inhibition with olaparib plus antihormonal therapy with abiraterone resulted in significantly prolonged radiologic progression-free survival (rPFS) compared with abiraterone alone among patients with metastatic castration-resistant prostate cancer (mCRPC).

Read more

June 14, 2018

Treatment with docetaxel without prednisone failed to improve biochemical disease-free survival (DFS) compared with surveillance in patients who had undergone radical prostatectomy with androgen deprivation therapy for intermediate- or high-risk prostate cancer.

Read more

June 4, 2018

Sunitinib alone was not inferior to cytoreductive nephrectomy (CN) followed by sunitinib with regard to overall survival in a phase III trial of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC).

Read more

June 4, 2018

Sunitinib alone was not inferior to cytoreductive nephrectomy (CN) followed by sunitinib with regard to overall survival in a phase III trial of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC).

Read more

May 15, 2018

Strong evidence exists to recommend ADT plus docetaxel or abiraterone compared with ADT alone.

Read more

May 14, 2018

One of the most challenging aspects of prostate cancer management in the nonmetastatic setting is also one of its greatest strengths: the myriad choices patients and providers face.

Read more

May 14, 2018

Rare genitourinary neoplasms encompass diseases of the kidney, bladder, prostate, and penile tract that are of uncommon histology. These entities often pose a major diagnostic and treatment dilemma to the treating physician.

Read more

May 11, 2018

Shilpa Gupta, MD, answers a question posed by an attendee during a Best of ASCO® Meeting.

Read more
June 5, 2017

The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival benefit compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals.

Read more
June 4, 2017

In patients with upper tract urothelial carcinoma or who have early onset bladder cancer, screening for Lynch syndrome and germline testing is highly recommended.

Read more

June 4, 2017

Adding abiraterone to androgen-deprivation therapy increased overall survival among men with locally advanced or hormone-sensitive metastatic prostate cancer.

Read more
May 25, 2017

Interdisciplinary experts to discuss key issues related to the incorporation of new diagnostic radiopharmaceuticals in the treatment of patients with cancer during ASCO/SNMMI joint session.

Read more
May 25, 2017

Dr. Ulka Vaishampayan discusses the current state of advanced prostate cancer treatment and the need to focus on the optimization of systemic therapies. 

Read more

May 25, 2017

CT imaging is widely available and contains quantitative information, particularly with respect to measuring changes in tumor size. However, there are many differences in how tumor size and response are assessed in clinical trials compared with clinical practice.

Read more
April 7, 2017

The 2017 Genitourinary Cancers Symposium featured a wide variety of novel and important research across a variety of specific fields.

Read more
April 7, 2017

Dr. Neha Vapiwala highlights the findings from the ProtecT trial, which compared surgery, radiation, and active surveillance for the treatment of localized prostate cancer.

Read more

April 7, 2017

Robert Dreicer, MD, MS, FACP, FASCO, answers a question posed by an attendee during a Best of ASCO Meeting.

Read more